血浆中CAP2基因表达在肝癌诊断中的价值

Values of CAP2 expression in plasma in the diagnosis of hepatocellular carcinoma

目的:检测腺苷酸环化酶相关蛋白2(CAP2)mRNA在血浆中表达情况,探讨其在肝癌诊断中的价值。方法:采用ELISA方法和实时荧光定量PCR分别检测61例肝癌患者、29例肝硬化患者及30例正常人血浆AFP和CAP2 mRNA的表达情况。结果:肝癌患者、肝硬化患者、正常人CAP2 mRNA阳性率分别为73.7%、41.4%、20.0%,差异有统计学意义(P<0.05);CAP2 mRNA在AFP阴性肝癌诊断敏感度为81.5%。AFP诊断敏感度为55.7%。联合检测CAP2 mRNA和AFP敏感度为91.8%。结论:检测血浆CAP2 mRNA有助于诊断肝癌,尤其是AFP阴性肝癌患者的诊断,联合CAP2 mRNA和AFP可提高肝癌的诊断率。

Objective ： To detect expression of cyclase-associated protein 2 （CAP2） in plasma and explore its values in diagnosis of hepatocellular carcinoma. Methods ： 61 patients with hepatocellu- lar carcinoma（HCC）, 29 cirrhosis patients and 30 healthy individuals were selected. AFP levels in plasma were measured by enzyme-linked immunosorbent assay （ELISA） and expression of CAP2 mRNA was detected by real-time PCR. Results ： Positive rates of CAP2 mRNA were 73.7% in HCC patients, 41.4% in cirrhotic patients and 20.0% in healthy individuals, significant differ- ences of expression of CAP2 mRNA were found in three groups （P 〈 0.05） ; CAP2 mRNA had a sensitivity of 81.5% for diagnozing AFP-negative HCC. In contrast, AFP had a sensitivity of 55.7% in differentiated HCC. In addition, the sensitivity of AFP combined with CAP2 mRNA was 91.8% for HCC patients. Conclusion ： Detection of CAP2 mRNA in plasma could contribute to conducive for the diagnosis of HCC, especially for the diagnosis of AFP-negative HCC patients. The combination of CAP2 mRNA and AFP could improve the diagnosis of HCC.